Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of prognostic factors for survival. We found that LDH 4330 U/l (1.5 times the upper limit of normal at our institution), older age, active disease, peripheral stem cell graft and male-to-male transplant were significant adverse predictors of survival. After accounting for LDH, other factors such as disease status and cytogenetics were not significantly associated with the outcome of BMT. All but one patient with an LDH 4330 U/l had active disease. However, when patients in CR were excluded, LDH 4330 U/l remained a significant adverse predictor of overall survival (hazard ratio 2.70, 95% confidence interval 1.41-5.16, P ¼ 0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts.
Introduction
The prognosis of patients with AML treated with chemotherapy depends largely on age and cytogenetic risk profile. These factors also predict outcome after allogeneic BMT in first complete remission. [1] [2] [3] [4] Other factors that also predict outcome after BMT for AML, include duration of first complete remission, 5, 6 disease status (remission or not), 7, 8 disease burden at the time of transplant 9,10 and transplant center experience. 6 Other factors that may predict prognosis in AML treated with a BMT are not as well described. For example, the German AML Cooperative Group demonstrated lower remission and higher relapse rates in patients with AML and lactate dehydrogenase levels (LDH) greater than three times the upper limit of normal. 11 Our group, and others, has confirmed this finding in older patients with AML. 12, 13 However, to our knowledge, LDH has not been explored as a prognostic factor for outcome following BMT. We, therefore, included LDH in an analysis of prognostic factors for survival of recipients of BMT for AML.
Materials and methods
From August 1991 to July 2005, 120 patients with AML were treated with non-T-cell depleted, HLA-matched sibling BMT. We excluded seven patients who were not treated with a BU-based preparative regimen and one patient in remission who was neither in a first nor in a second complete remission. Thus, we analyzed 112 patients for prognostic factors for outcome following BMT. After BMT, patient data were captured prospectively and accessed through the Cleveland Clinic Transplant Center Unified Transplant Database. All patients were treated on clinical trials approved by the Institutional Review Board of the Cleveland Clinic, and all patients provided signed informed consent.
Serum levels of LDH were obtained at the time of admission to the inpatient BMT unit.
Cytogenetic classification
The results of karyotype analysis at the time of diagnosis were reviewed and categorized as either good, intermediate or poor risk according to the Southwest Oncology Group/ Eastern Cooperative Oncology (SWOG/ECOG), 14 Cancer and Leukemia Group B (CALGB) 15 and Medical Research Council of Great Britain (MRC) 16 criteria.
Disease status
Patients without evidence of AML by BM aspirate and biopsy within 1 month of admission for BMT were considered in remission regardless of peripheral blood cell counts. Any evidence of AML in the marrow, blood or an extramedullary site at the time of admission for BMT was considered active disease.
Preparative regimen
Patients were treated with BU 16 mg/kg and cyclophosphamide 120 mg/kg or a regimen consisting of BU 14 mg/kg, cyclophosphamide 120 mg/kg and VP-16 50 mg/kg. These regimens have equivalent efficacy and are considered together for this analysis. 17 
GVHD prophylaxis
Patients were treated with a combination of cyclosporine (3 mg/kg/day) and either mini-dose methotrexate (5 mg/m 2 IV on days 1, 3, 6 and 11) or mycophenolate (1500 mg/day orally). 18 No donor graft was T-cell depleted.
Supportive care
All patients were managed in a dedicated BMT unit in laminar airflow rooms with standard infection control procedures. All patients received G-CSF to accelerate neutrophil recovery after BMT, and weekly intravenous gammaglobulin while hospitalized, then weekly until 100 days after BMT. Patients with serologic evidence of exposure to CMV þ , or exposure to a CMV þ donor, were treated prophylactically with ganciclovir upon engraftment until 100 days after BMT.
Patient evaluation
Acute and chronic GVHD were diagnosed clinically and with histologic confirmation whenever possible. Patients were followed from the day of transplant until pathologic evidence of leukemic progression or relapse (progression-free survival) and/or until death (overall survival).
Statistics
Categorical variables are summarized as frequency counts and percentages. Continuous variables are summarized as the mean and s.d. or the median and range, as appropriate. Survival was calculated from the transplant date to either the date of death or date of last follow-up. Progression-free survival was calculated from the transplant date to either the date of progression, the date of death or the date of last follow-up. Outcomes were estimated using the Kaplan-Meier method, and compared according to specific variables using the log-rank test. Cox proportional hazards analysis was used to identify univariable and multivariable prognostic factors for the two outcomes. Thirteen factors were considered in univariable analysis: gender, age, number of prior chemotherapy regimens, prior radiation therapy, months from diagnosis to transplant, pre-admission LDH, disease status, CALGB cytogenetic classification, MRC classification, SWOG classification, preparative regimen, source of hematopoietic cells and donor-to-patient gender. LDH was analyzed both as a continuous variable and as either less than or greater than 1.5 times the upper limit of normal at our institution (100-220 U/l). For the multivariable analysis, a stepwise procedure was used with a variable entry criterion of 0.10 and a retention criterion of 0.05. Results are presented as the hazard ratio (HR), 95% confidence interval (CI) and P-value. The three cytogenetic classifications were not prognostic, and were missing on about one-third of patients, therefore, they were not included in multivariable analysis. Data were analyzed using SAS s software (SAS Institute Inc., Cary, NC, USA); all statistical tests were two-sided and Po0.05 was used to indicate statistical significance.
Results
The characteristics of the 112 study patients are listed in Table 1 . More patients had active disease than were in remission at the time of BMT. Most patients had intermediate risk cytogenetics by SWOG, CALGB or MRC criteria, but the fewest patients were categorized as poor risk by the MRC criteria. Only eight patients received peripheral stem cells, while the rest received BM.
One patient with AML arising from a myeloproliferative disorder experienced graft failure. Acute GVHD occurred in 59% of patients (grades 2-4 in 44%). Chronic GVHD was detected in 57% of patients who survived at least 100 days post transplant (extensive in 36%).
Relapse occurred in 35% of patients and was the cause of death in 30 patients, accounting for 42% of documented deaths. Of the other 58% of patients who died, the predominant causes were GVHD (25%) and infection (18%). Among 16 patients with an LDH level 41.5 Â the upper limit of normal, 15 have died. The cause of death was relapse in 10, infection in two, hepatic failure in two and GVHD in one.
With a median of 60 (range 4-155) months of follow-up, patients in CR1, CR2 and with active disease had 3 year overall survivals of 55, 40 and 26%, respectively.
Univariable analysis identified male gender, older age, active disease at the time of BMT, an LDH 4330 U/l (1.5 Â normal), peripheral stem cell graft and a male-tomale transplant as adverse prognostic factors for survival (Table 2) . Cytogenetic risk by any classification scheme was not a significant factor.
In multivariable analysis, only older age, LDH 4330 U/ l, peripheral stem cell graft and male-to-male transplant retained significance as adverse predictors of survival ( Table 2 ). All patients but one with a high LDH had active disease at the time of BMT. However, when patients in CR1 were excluded, LDH 4330 U/l remained significantly associated with worse overall survival (HR 2.70, 95% CI 1.41-5.16, P ¼ 0.003). Among patients treated with active disease, those with an LDH o 330 U/l had a median overall survival of 13 months, compared to a median of 4.1 months for those patients with an LDH 4330 U/l (P ¼ 0.003) (Figure 1 ). In contrast, the median overall survival for patients in CR with an LDH o300 U/l was 43.5 months. When we added a variable to the model to account for the year the transplant was performed, there was no significant change to our results (P ¼ 0.80).
The median LDH level was within the normal range for our institution of 100-220 U/l. Sixteen patients were identified with an LDH level 41.5 times the upper limit of normal (4330 U/l) at the time of admission for BMT. The median BM blast count of these 16 patients was 18% (range 0-88%) and the median absolute peripheral blood blast count was 3.61/ml (range 0-44.7/ml) at the time of BMT. There was no significant difference in median serum levels of aspartate transaminase or alkaline phosphatase between those patients with an LDH level 4330 U/l and those with lower levels of LDH (22 versus 21, P ¼ 0.48 and 107 versus 88, P ¼ 0.31, respectively).
Discussion
LDH levels are predictive of prognosis in such diverse malignancies as germ cell tumor, 19, 20 non-Hodgkin's lymphoma 21, 22 and small cell lung cancer. 23 We have also previously demonstrated the adverse predictive value of a high LDH level before autologous stem cell transplant for non-Hodgkin's lymphoma. 24, 25 Recently, an increased LDH level was shown to adversely influence survival following reduced intensity allogeneic stem cell transplant in a heterogenous population of patients 30% of whom had acute leukemia. 26 LDH has not been previously examined as a potential risk factor for outcome after BMT for AML. Our data suggest that high LDH levels independently portend a poor prognosis following allogeneic BMT for AML.
All but one of our patients with a high LDH had active disease at the time of BMT. A high LDH level may simply reflect a high tumor burden reflected in a high blast percentage. However, the marrow blast percentage may change between the time the biopsy is obtained and the patient's preparative regimen is started. Furthermore, the peripheral blood blast count can be manipulated with chemotherapy, hydroxyurea or leukopheresis. Finally, the patients in our series with an LDH 4330 U/l did not seem to have a particularly high burden of blasts. These Table 1 Characteristics of 112 patients treated with matched sibling allogeneic bone marrow transplant observations suggest that an LDH level greater than 1.5 times the upper limit of normal may be a more important and reliable predictor of poor outcome than the presence or quantity of leukemic blasts. Our study also found that transplant from a male donor to a male recipient predicted for a worse outcome compared to other possible donor/recipient gender pairings. This was unexpected since previous studies have shown that a female donor to a male recipient resulted in worse outcomes due to a higher incidence of GVHD. 27 However, female sex has been identified as a favorable risk factor for long-term survival after treatment for AML. 28 We also found that a donor graft derived from PBSCs predicted a worse outcome than a graft derived from BM. Others have found a benefit to PBSCs in the setting of advanced leukemia. [29] [30] [31] However, there were only eight PBSC grafts in our series and the significance of our observation is uncertain.
Advancing age is often cited as an indicator of poor prognosis following BMT. Yet, older patients with AML are also more likely to have intrinsically more resistant leukemias due, at least in part, to adverse cytogenetic profiles. 32 This association confounds the prognostic importance of age alone. Some studies have clearly identified worse survival following BMT in patients older than 40 years, 2, 3, 6 while others have found no adverse effect of age in patients younger than 40 years. 33, 34 We found that for every 10-year increase in age, survival after BMT worsened.
Several studies, and a recent meta-analysis, have concluded that outcome after BMT for AML depends on cytogenetic risk. 1, 3, 4, 34, 35 In contrast, we found no cytogenetic risk group independently predicted for survival. An exception to this finding may be the poor-risk patients with active disease as defined by the MRC who tended to have a worse prognosis compared to patients classified as either good or intermediate with active disease (P ¼ 0.052). While our findings may reflect a relatively small population of patients, another study of 93 AML patients treated with BMT in Canada also found no correlation of cytogenetic profile with outcome. 36 Conflicting findings with regard to cytogenetics between different studies may reflect heterogenous patient populations, varied transplant techniques, disease status at the time of BMT or cytogenetic classification system employed.
The presence of active disease at the time of transplant is another important adverse prognostic factor. In collaboration with our colleagues at the Ohio State University, we previously showed that heavily pretreated patients, and those with high disease burden, fared poorly after BMT. 9 Similar results were reported by Sierra et al. 10 who identified the presence of blasts in the peripheral blood as an adverse prognostic finding. While these studies explored blasts as a risk factor in the setting of matched unrelated donor BMT, there is no reason to think that the presence of blasts does not represent a similar adverse finding in sibling BMT. 37 Nonetheless, our data suggest those patients with active disease and an LDH level p330 U/l have a survival similar to that achieved by patients in remission at the time of BMT. On the basis of our analysis, we conclude that a high LDH level is an important independent predictor of poor survival after sibling BMT for AML. This observation is based on a relatively small number of patients and should be verified in a larger, prospective study of patients. LDH should be included as part of any future analysis of prognosis following BMT for AML. Whether or not patients with a high LDH should be excluded from BMT is a matter of debate since one of our patients managed to survive. However, clinicians should engage AML patients with a high LDH in a meaningful discussion of risks and benefits before proceeding with BMT. 
